Eyenovia buys US commercialisation rights to Formosa’s APP13007
Under the agreement, US-based Eyenovia has obtained the exclusive US rights to distribute and sell APP13007 in a…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
17 Aug 23
Under the agreement, US-based Eyenovia has obtained the exclusive US rights to distribute and sell APP13007 in a…
17 Aug 23
The funds raised will be allocated to several crucial endeavours. Firstly, they will facilitate the successful conclusion of…
17 Aug 23
Day One receives an exclusive license to develop and commercialize small molecule drug candidates for pediatric and adult…
16 Aug 23
The partnership involves three separate multi-year collaborations, which allow Tentarix to receive a total of $66m in upfront…
16 Aug 23
Under the terms of the alliance, Parexel will serve as the preferred CRO provider for the Partex group…
16 Aug 23
The partnership enables CytoMed to leverage CNK's PiggyBac technology, leveraging a non-viral gene editing approach, to permanently integrate…
16 Aug 23
The agreement offers Gritstone bio unrestricted access to Genevant's LNP technology, which will be applied alongside Gritstone bio's…
16 Aug 23
Under the agreement, AGC Biologics will leverage our monoclonal antibody development and manufacturing experience to perform process transfer,…
16 Aug 23
Precision Eligible to Receive up to $227m in Upfront Economics and Milestone Payments for Azer-Cel in Addition to…
14 Aug 23
The FDA approval is based on the Phase 3 MAGNITUDE study, in which Akeega plus prednisone significantly improved…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates